Print

Primary Objective:

To assess, in the same study, the safety of sarilumab and tocilizumab in patients with rheumatoid arthritis (RA) who are inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.

Read more: http://www.clinicaltrials.gov/ct2/show/NCT01768572?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30